Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Safety and Efficacy of Tegileridine in Painless Gastrointestinal Endoscopy

13. november 2026 oppdatert av: Fangpeng Gao, Hainan Medical College

This single-center, randomized, double-blind, active-controlled clinical trial aims to evaluate the safety and efficacy of tegileridine, a biased μ-opioid receptor agonist, in patients undergoing gastrointestinal endoscopy under sedation, compared with sufentanil. A total of 338 patients scheduled for gastrointestinal endoscopy under sedation were enrolled and randomly assigned in a 1:1 ratio to receive either tegileridine or sufentanil. The primary outcome is the incidence of respiratory depression. Secondary outcomes include the incidences of hypotension and postoperative nausea and vomiting, sedation success rate, supplemental propofol dose, procedure duration, recovery time, and patient satisfaction. This study will provide clinical evidence to support individualized and precision-based anesthesia strategies for gastrointestinal endoscopy.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Background: Gastrointestinal endoscopy under sedation is a cornerstone of the diagnosis and treatment of digestive diseases, reducing patient discomfort and improving adherence. Conventional anesthesia with sufentanil and propofol is associated with significant adverse effects, including respiratory depression, gastrointestinal adverse reactions, postoperative nausea and vomiting (PONV), and hemodynamic fluctuations. Tegileridine mediates analgesia through preferential activation of G protein signaling at the μ-opioid receptor while reducing β-arrestin pathway activation, thereby lowering the risks of gastrointestinal adverse reactions and respiratory depression. To date, no clinical studies have investigated tegileridine for gastrointestinal endoscopy under sedation, and pharmacokinetic data and dose-adjustment guidelines for older adults remain unavailable.

Objectives: To systematically compare the safety and efficacy of tegileridine and sufentanil for gastrointestinal endoscopy under sedation, establish the suitability of tegileridine in this setting, and determine an appropriate dose for older patients, thereby supporting the development of individualized and precision-based anesthesia strategies.

Study Design: This is a single-center, randomized, double-blind, active-controlled trial. A total of 338 patients scheduled for gastrointestinal endoscopy under sedation will be enrolled and randomly assigned in a 1:1 ratio to the tegileridine group or the sufentanil group. Participants, staff involved in administering sedation, and outcome assessors will be blinded to treatment allocation. Only the nurses responsible for preparing the study medications will be unblinded.

Study Population: Eligible patients will be aged 18-75 years, have a body mass index (BMI) of 18.0-28.0 kg/m², a Mallampati airway classification of I or II, and an American Society of Anesthesiologists (ASA) physical status classification of I or II, have no contraindications to routine gastroscopy, and provide written informed consent. Exclusion criteria include severe cardiopulmonary disease, hepatic or renal failure, a history of opioid allergy, chronic opioid dependence, hypokalemia, a history of QT interval prolongation, pregnancy, and breastfeeding. Patients whose gastroscopy lasts longer than 30 minutes or who experience adverse events that cannot be resolved with treatment will be withdrawn from the study.

Interventions: Patients in the tegileridine group will receive intravenous tegileridine at 0.01 mg/kg, followed 3 minutes later by intravenous propofol at 1.5 mg/kg. Patients in the sufentanil group will receive intravenous sufentanil at 0.1 μg/kg, followed 3 minutes later by intravenous propofol at 1.5 mg/kg. The procedure will begin once the eyelash reflex is absent and the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score is ≤3. If signs of inadequate anesthesia occur during the examination, such as body movement, coughing, or a heart rate >100 beats/min, supplemental propofol at 0.5-1.0 mg/kg will be administered at intervals of at least 2 minutes.

Outcome Measures: The primary outcome is the incidence of respiratory depression, defined as a respiratory rate <8 breaths/min or peripheral oxygen saturation (SpO₂) <90%. Secondary outcomes include safety measures (hypotension, PONV, the need for airway interventions, and changes in vital signs at multiple time points), efficacy measures (sedation success rate, the number of supplemental propofol doses and total propofol dose, procedure duration, and recovery time), and patient satisfaction, assessed on a scale of 1-10.

Expected Results: Compared with the sufentanil group, the tegileridine group is expected to have a lower incidence of respiratory depression, a lower risk of PONV, and more stable vital signs while achieving adequate analgesia for gastrointestinal endoscopy under sedation. Tegileridine may therefore offer a safer anesthesia option for older patients and patients with obesity.

Studietype

Intervensjonell

Registrering (Antatt)

338

Fase

  • Fase 4

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Fang Peng Gao, MS
  • Telefonnummer: 17760577442
  • E-post: gao1664@163.com

Studiesteder

    • Hainan
      • Haikou, Hainan, Kina, 570311
        • Rekruttering
        • The Second Affiliated Hospital of Hainan Medical University
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 75 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Patients aged 18-75 years scheduled for gastrointestinal endoscopy under sedation.
  2. Body mass index (BMI) of 18.0-28.0 kg/m².
  3. Mallampati airway classification of I or II.
  4. American Society of Anesthesiologists (ASA) physical status classification of I or II.
  5. No contraindications to routine gastroscopy.
  6. Written informed consent signed by the patient and their family member.

Exclusion Criteria:

  1. Severe cardiopulmonary disease.
  2. Hepatic or renal failure.
  3. History of opioid allergy.
  4. Chronic opioid dependence.
  5. Hypokalemia or a history of QT interval prolongation.
  6. Pregnancy or breastfeeding.

Withdrawal Criteria:

  1. Gastroscopy duration exceeding 30 minutes.
  2. Adverse events that cannot be resolved with treatment.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Tegileridine Group

Tegileridine 0.01 mg/kg will be administered intravenously, followed 3 minutes later by intravenous propofol 1.5 mg/kg.

Tegileridine 0.01 mg/kg will be administered intravenously, followed 3 minutes later by intravenous propofol 1.5 mg/kg to induce sedation. The procedure will begin once the eyelash reflex is absent and the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score is ≤3. If signs of inadequate anesthesia occur during the examination, such as body movement, coughing, or a heart rate >100 beats/min, supplemental intravenous propofol 0.5-1.0 mg/kg will be administered at intervals of at least 2 minutes.

Tegileridine 0.01 mg/kg or sufentanil 0.1 μg/kg will be administered intravenously, followed 3 minutes later by intravenous propofol 1.5 mg/kg to induce sedation. The procedure will begin once the eyelash reflex is absent and the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score is ≤3. If signs of inadequate anesthesia occur during the examination, such as body movement, coughing, or a heart rate >100 beats/min, supplemental intravenous propofol 0.5-1.0 mg/kg will be administered at intervals of at least 2 minutes.

Aktiv komparator: Sufentanil Group

Sufentanil 0.1 μg/kg will be administered intravenously, followed 3 minutes later by intravenous propofol 1.5 mg/kg.

Tegileridine 0.01 mg/kg or sufentanil 0.1 μg/kg will be administered intravenously, followed 3 minutes later by intravenous propofol 1.5 mg/kg to induce sedation. The procedure will begin once the eyelash reflex is absent and the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score is ≤3. If signs of inadequate anesthesia occur during the examination, such as body movement, coughing, or a heart rate >100 beats/min, supplemental intravenous propofol 0.5-1.0 mg/kg will be administered at intervals of at least 2 minutes.

Sufentanil 0.1 μg/kg will be administered intravenously, followed 3 minutes later by intravenous propofol 1.5 mg/kg to induce sedation. The procedure will begin once the eyelash reflex is absent and the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score is ≤3. If signs of inadequate anesthesia occur during the examination, such as body movement, coughing, or a heart rate >100 beats/min, supplemental intravenous propofol 0.5-1.0 mg/kg will be administered at intervals of at least 2 minutes.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of Respiratory Depression
Tidsramme: Periprocedural, up to 2 hours

The primary outcome is the incidence of respiratory depression, defined as a respiratory rate <8 breaths/min or peripheral oxygen saturation (SpO₂) <90%.

Periprocedural, up to 2 hours

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of Hypotension
Tidsramme: Periprocedural, up to2 hours

Hypotension is defined as a decrease in systolic blood pressure (SBP) of more than 20% from baseline. The incidence of hypotension will be assessed during the periprocedural observation period and reported as the percentage of participants experiencing at least one episode of hypotension.

Periprocedural, up to2 hours
Incidence of Postoperative Nausea and Vomiting (PONV)
Tidsramme: Periprocedural, up to 24 hours after the endoscopic procedure

The incidence of postoperative nausea and vomiting (PONV) will be assessed within 24 hours after completion of the endoscopic procedure. PONV is defined as the occurrence of at least one episode of nausea, vomiting, or both during the observation period. The outcome will be reported as the percentage of participants experiencing PONV.

Periprocedural, up to 24 hours after the endoscopic procedure
Heart Rate
Tidsramme: Periprocedural, up to 2hours

Heart rate (beats/min) will be recorded at six prespecified time points: before entering the procedure room, after anesthesia induction, at endoscope insertion, 2 minutes after endoscope insertion, at endoscope withdrawal, and upon leaving the procedure room.

Periprocedural, up to 2hours
Mean Arterial Pressure
Tidsramme: Periprocedural, up to 2 hours

Mean arterial pressure (MAP, mmHg) will be recorded at the following six prespecified time points: before entering the procedure room, after anesthesia induction, at endoscope insertion, 2 minutes after endoscope insertion, at endoscope withdrawal, and upon leaving the procedure room.

Periprocedural, up to 2 hours
Respiratory Rate
Tidsramme: Periprocedural, up to 2 hours

Respiratory rate (breaths/min) will be recorded at six prespecified time points: before entering the procedure room, after anesthesia induction, at endoscope insertion, 2 minutes after endoscope insertion, at endoscope withdrawal, and upon leaving the procedure room.

Periprocedural, up to 2 hours
Peripheral Oxygen Saturation
Tidsramme: Periprocedural, up to 2 hours

Peripheral oxygen saturation (SpO₂, %) will be recorded at six prespecified time points: before entering the procedure room, after anesthesia induction, at endoscope insertion, 2 minutes after endoscope insertion, at endoscope withdrawal, and upon leaving the procedure room.

Periprocedural, up to 2 hours
Percentage of Participants With Successful Sedation Based on Body Movement at Endoscope Insertion and Rescue Sedative Use
Tidsramme: Periprocedural, at endoscope insertion for body movement and throughout the endoscopic procedure for rescue sedative use. Sedation success is determined at procedure completion.

Percentage of participants who meet both criteria for successful sedation: no body movement at endoscope insertion and no use of any rescue sedative other than the study drug during the endoscopic procedure.

Periprocedural, at endoscope insertion for body movement and throughout the endoscopic procedure for rescue sedative use. Sedation success is determined at procedure completion.
Number of Supplemental Propofol Doses and Total Propofol Dose
Tidsramme: Periprocedural, up to 2 hours

The number of supplemental propofol doses administered during the endoscopic procedure will be recorded for each participant. The total propofol dose (mg), including the initial dose and all supplemental doses, will also be calculated. Both outcomes will be assessed at the completion of the endoscopic procedure.

Periprocedural, up to 2 hours
Procedure Duration
Tidsramme: During the endoscopic procedure

Procedure duration is defined as the time interval from endoscope insertion to endoscope withdrawal, measured in minutes.

During the endoscopic procedure
Recovery Time
Tidsramme: Periprocedural,up to 2 hours

Recovery time is defined as the time interval from endoscope withdrawal to the time when the participant first meets the predefined discharge criteria for the post-anesthesia care unit (PACU), measured in minutes.

Periprocedural,up to 2 hours
Patient Satisfaction
Tidsramme: Post-procedure assessment.
Post-procedure assessment.
Sedation Success Rate
Tidsramme: At the end of the procedure.
At the end of the procedure.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

6. juni 2026

Primær fullføring (Antatt)

10. november 2026

Studiet fullført (Antatt)

30. november 2026

Datoer for studieregistrering

Først innsendt

28. oktober 2026

Først innsendt som oppfylte QC-kriteriene

13. november 2026

Først lagt ut (Faktiske)

18. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

13. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 2026-K68-01

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .